Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Four Boston Biotechs That Could Make M&A Moves This Year

July 29, 2015By Alex Keown, Breaking News Staff BOSTON – It’s been the year of deal making with more than $220 billion spent on mergers and acquisitions in the biotech industry, and it’s not over yet. Although no M&A activity has been announced, at least as of this writing, but given the atmosphere that […]

Read More »

Vertex Revenue Rises 20%

By Tess Stynes The Wall Street Journal Biography @TessStynes July 29, 2015 4:42 p.m. ET   Vertex Pharmaceuticals Inc. said its second-quarter revenue rose 20% on strong sales of Kalydeco that led the biotechnology company to raise its 2015 sales guidance for the cystic-fibrosis drug. Shares rose 1.5% to $127.50 in recent after-hours trading […]

Read More »

Teva Pharmaceuticals Stands To Lose Around $300 Million On Mylan Trade

Teva Pharmaceutical Industries may have found the deal it wanted in purchasing Allergan’s generics business for $40.5 billion in cash and stock, but the Israeli pharmaceutical company stands to lose around $300 million from its tactics in a now withdrawn unsolicited bid for competitor Mylan. Such are the costs of dealmaking in the red hot pharmaceutical and […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom